Your session is about to expire
← Back to Search
Chemotherapy Combination for Bladder Cancer
Study Summary
This trial is studying a combination of drugs as a possible treatment for adenocarcinoma of the urothelium or urachal remnant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My overall health is good enough for treatment, including my blood, liver, and kidney functions.My brain metastases are not under control.My cancer can be measured in two ways and meets size requirements.My heart is functioning well despite my history of heart issues.I am 18 years old or older.My cancer started outside the urinary tract and has spread to my bladder.I do not have a severe illness that would stop me from completing the treatment.It's been over 6 weeks since my pelvic radiation, and less than 10% of my bone marrow was irradiated.My cancer, which is mostly adenocarcinoma, started in the urinary tract.My cancer has spread or cannot be removed with surgery.I am mentally capable of understanding and consenting to participate.I do not have another cancer that could affect my treatment.
- Group 1: 5-FU, Leucovorin, Gemcitabine + Cisplatin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the most common Gemcitabine side effects that patients experience?
"While there is some evidence that gemcitabine is safe, it did not receive a higher score because this drug is still in Phase 2 clinical trials. This means that, while there are animal studies and small human trials supporting safety, large-scale efficacy has yet to be proven."
For what purpose is Gemcitabine most often leveraged?
"Gemcitabine has been shown to be an effective treatment against malignant neoplasms of the pancreas, urinary bladder, and neoplasm metastasis."
What is the target sample size for this research?
"This study has wrapped up its participant recruitment. However, if you're still interested in other trials, there are 1176 and 1305 respectively for cancer of the urethra and Gemcitabine that are ongoing."
Are patients able to enroll in this clinical trial at this time?
"This study is no longer recruiting patients. According to the clinical trial information first posted on April 1st, 2003 and last edited on October 20th, 2022, this study has ended. However, there are 1176 other studies involving cancer of the urethra that are actively recruiting participants and 1305 trials for Gemcitabine currently admitting patients."
Share this study with friends
Copy Link
Messenger